Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. director Michael David Varney received a stock option award reported as of January 29, 2026. The option covers 96,000 shares of common stock at an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48th of the option vests each month on the 29th day (or the last day of February), beginning in February 2026, so long as Varney continues providing service to Erasca on each vesting date.
Erasca, Inc. reported a stock option grant to its General Counsel and Corporate Secretary, Ebun Garner. The option covers 560,000 shares of Erasca common stock at an exercise price of $10.31 per share and was granted on January 29, 2026.
According to the vesting terms, 1/48th of the shares subject to the option vest monthly on the 29th of each month (or the last day of February), beginning in February 2026, as long as Garner remains in continuous service with the company. After this grant, Garner beneficially owns 560,000 stock options directly.
Erasca, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company also closed an upsized public offering of 25,875,000 common shares, including underwriters’ full overallotment exercise.
Erasca estimates net proceeds of $242.7 million from this January 2026 offering after underwriting discounts and expenses. Based on this cash position and the offering proceeds, the company estimates it has sufficient cash resources to fund operations into the first half of 2029. These figures are preliminary, unaudited and subject to completion of year-end financial procedures.
Erasca, Inc. entered into an underwriting agreement to sell 22,500,000 shares of its common stock at a public offering price of $10.00 per share, with underwriters purchasing at $9.40 per share. The company also granted the underwriters a 30-day option to buy up to 3,375,000 additional shares at the same public price, less discounts and commissions. Net proceeds to Erasca are expected to be about $211.0 million, or approximately $242.7 million if the option is fully exercised, after fees and expenses. The offering is expected to close on January 23, 2026, subject to customary closing conditions, and is being conducted under an effective shelf registration statement and related prospectus supplement.
Erasca, Inc. is conducting a primary offering of 22,500,000 shares of its common stock at $10.00 per share, for gross proceeds of $225.0 million and estimated net proceeds of about $211.0 million after underwriting fees and expenses. The company has granted underwriters a 30‑day option to purchase up to 3,375,000 additional shares.
Erasca plans to use the net proceeds, together with its existing cash, cash equivalents and marketable securities, to fund research and development of its oncology product candidates and other programs, and for working capital and general corporate purposes, with potential in-licensing or acquisitions as opportunities arise. As of September 30, 2025, Erasca had 283,711,805 shares outstanding, and investors in this offering will experience immediate dilution, with an estimated $8.18 per-share dilution based on the net tangible book value at that date.
Erasca, Inc. reported preliminary year-end liquidity, stating that as of December 31, 2025, its cash, cash equivalents and marketable securities totaled approximately $341.8 million. This figure is based on unaudited internal information and management estimates and is part of the company’s results of operations and financial condition disclosure.
The company emphasized that this amount may change once it completes its year-end financial closing procedures and reviews of internal controls, and after its independent registered public accounting firm conducts its audit. The disclosure is deemed filed under the securities laws and is subject to the usual forward-looking statement cautions and risk factors referenced from prior SEC filings.
Erasca, Inc. is conducting a primary offering of $150,000,000 of its common stock under a shelf registration, with underwriters holding an option to buy up to an additional $22,500,000 of shares from the company.
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes three clinical-stage programs—ERAS-0015 (pan-RAS molecular glue), ERAS-4001 (pan-KRAS inhibitor) and naporafenib (pan-RAF inhibitor)—plus ERAS-12, an EGFR D2/D3 biparatopic antibody in discovery.
As of September 30, 2025, Erasca had 283,711,805 shares of common stock outstanding and net tangible book value of approximately $347.9 million, or $1.23 per share. A preliminary update indicates cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company plans to use offering proceeds, together with existing cash, to fund research and development, other programs, working capital and general corporate purposes, and may also in-license or acquire complementary assets. The company warns of immediate and substantial dilution to new investors and highlights significant risks associated with this offering.
Erasca Foundation has filed a notice of proposed sale under Rule 144 covering 8,333 shares of Erasca, Inc. common stock. The shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $68,573.87 and an approximate sale date of 01/15/2026. The filing notes that 283,711,805 shares of this class were outstanding.
The securities to be sold come from a larger block of 10,193,557 common shares that the foundation acquired as a donation from Erasca, Inc. on 07/20/2021. Over the past three months, Erasca Foundation has already sold 8,333 shares on each of 10/15/2025, 11/17/2025, and 12/15/2025, with gross proceeds of $20,591.33, $21,626.50, and $30,438.69, respectively.
Erasca, Inc. received a Schedule 13G reporting that Paradigm BioCapital entities and Senai Asefaw, M.D. collectively beneficially own 15,159,095 shares of its common stock. This represents 5.3% of Erasca’s outstanding common shares, based on 283,711,805 shares reported outstanding as of November 5, 2025.
Within this total, Paradigm BioCapital International Fund Ltd. directly holds 13,377,027 shares, or 4.7% of the class, while additional shares are held in separately managed accounts overseen by Paradigm BioCapital Advisors LP. The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Erasca, indicating a passive investment intent.
Erasca, Inc. filed a report highlighting new clinical progress and upcoming milestones for its RAS-targeting drug pipeline and updating its investor presentation. The company reported that ERAS-0015, described as a potential best-in-class RAS-targeting molecule in the AURORAS-1 Phase 1 trial, is advancing dose escalation faster than anticipated, with ongoing confirmed and unconfirmed partial responses at doses starting from 8 mg once daily and a favorable safety profile with no dose-limiting toxicities at doses evaluated through a January 7, 2026 cutoff. Initial Phase 1 monotherapy data for ERAS-0015 in RAS-mutant solid tumors are planned in the first half of 2026, with expansion and combination cohorts through 2027. ERAS-4001, described as a potential first-in-class pan-KRAS inhibitor in the BOREALIS-1 Phase 1 trial, continues dose escalation and has planned monotherapy data in the second half of 2026 and further expansion work in 2027. Erasca also updated its corporate presentation, which will be used at the J.P. Morgan Healthcare Conference and posted on its website.